Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

STAMFORD, Conn., July 26, 2022 (GLOBE NEWSWIRE) — Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the second quarter of 2022 after the market close on Monday, August 15, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Richard Miao, Interim Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET.

Conference Call Details

Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the Sema4 investor relations website at https://ir.sema4.com/.

About Sema4

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.

Investor Relations Contact:
Joel Kaufman
Sema4
investors@sema4.com

Media Contact:
Radley Moss
Sema4
radley.moss@sema4.com

Staff

Recent Posts

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

50 minutes ago

Hologic Announces Financial Results for First Quarter of Fiscal 2026

– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…

54 minutes ago

Illumina completes acquisition of SomaLogic

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…

59 minutes ago

RazorMetrics Drives More Than $11 Million in Prescription Drug Savings for Ohio Plans and Residents

AUSTIN, Texas, Jan. 30, 2026 /PRNewswire/ -- RazorMetrics, a leading innovator in pharmacy cost containment…

59 minutes ago

NYSE Content Advisory: Pre-Market Update + Cast of HBO’s ‘Industry’ Rang Thursday’s Closing Bell

NEW YORK, Jan. 30, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a…

59 minutes ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national…

59 minutes ago